Extending the utility and durability of antifungal agents via innovative treatment regimens that minimise drug resistance

Lead Research Organisation: UNIVERSITY OF EXETER
Department Name: Biosciences

Abstract

A type of fungus called Candida, that lives on and in the human body, can sometimes cause fatal infections in humans, usually in patients who have suffered from a physical trauma or have weakened immunity.

When a Candida infection of the bloodstream or other normally sterile body site (invasive candidiasis) is detected, rapid treatment with antifungal drugs can be a lifesaving measure. Unfortunately, there are a limited number of effective drugs, and Candida species are becoming more resistant to them. This dilemma has recently been highlighted by the World Health Organisation as a public health crisis of growing concern.

Invasive candidiasis is the most common invasive fungal infection in the UK, with an estimated 5,000 cases each year. Critically ill patients in intensive care units are particularly vulnerable, with an estimated 30-40% of all infections occurring in this setting.
Unfortunately, even with the use of antifungal drugs, up to 50% of patients will not survive. Treatment options are limited with just four antifungal drug classes available; azoles; echinocandins; polyenes; nucleoside analogues. Preserving the effectiveness of these drugs is vital for ensuring we have viable treatment options to manage invasive candidiasis in the future. This is the overarching aim of this study.

There are several approaches that can be used to preserve the effectiveness of available antifungal drugs. One is to change the way in which they are used, preferably by reducing the frequency of use or the amount of drug needed to achieve an effect. Another is to combine different drug classes (called combination therapy). The best modifications of antifungal use will maintain antifungal activity but reduce the rate of emergence of drug resistance. To achieve this, we need a thorough understanding of how antifungal resistance (AFR) develops.

AFR can be defined as the ability of fungal cells to grow in the presence of high concentrations of antifungal drug. This behaviour can be readily studied in the lab since fungal cells can be grown very quickly (overnight) and we have many methods for observing their responses to antifungal drugs, such as microscopy and growth tests.

In this programme of work, we will connect three world class research centres in Liverpool, London and Exeter to discover new drugs and drug combinations that prevent fungal growth, and limit AFR. The first step will be to measure the growth of five different Candida species in the presence of various antifungal drugs and drug combinations, including new antifungal drugs that will soon come to market. The most effective drug treatments will then be progressed to study their effectiveness in a mouse model of invasive candidiasis.

By learning about the way that Candida species adapt to fungal drugs in the laboratory setting, in mice and in critically ill patients, we can develop new tests to recognise AFR early when this happens during an infection. By working as a team of scientists and clinicians we can share important knowledge and, informed by current practices, develop better tests for AFR. In turn this will help clinicians to detect AFR as it emerges during treatment, and to modify patients' treatment for a better outcome.

Technical Summary

Fungal diseases kill over one million people annually, but therapy is constrained to four drug classes, almost always used clinically as monotherapies. The utility of each drug class is being progressively compromised by the widespread emergence of antifungal resistance (AFR), contributing to recent declarations by the WHO and CDC that fungal infections have become a global health emergency. The WHO report highlighted five Candida species including C. auris, a new and commonly multidrug resistant species, C. albicans, C. glabrata, C. parapsilosis and C. tropicalis. In this programme we will work with all five species.

Antifungal regimens are optimised for antifungal efficacy, not resistance emergence. We hypothesise that:
a) Antifungal resistance (AFR) is not inevitable. The evolution and dissemination of drug-resistant phenotypes can be minimised given a better understanding of the pharmacological and pathophysiological mechanisms leading to the emergence of AFR
b) The utility and durability of antifungal agents can be extended using approaches that simultaneously optimise antifungal killing and mitigate antifungal resistance (AFR)

The major questions that we address are:
How do resistance trajectories of clinical Candida isolates become impacted by different types and durations of antifungal drug exposure?
How can antifungal regimens be optimised to best suppress this?

Using extant and soon-to-market antifungal drugs, we will define and parameterise via in vitro (WP1) and in vivo (WP2) analyses the antifungal efficacy and resistance liabilities of antifungal monotherapy, coupled to underlying mechanisms that are the most robustly indicative of resistance emergence and tractable to clinical monitoring (WP3). Against this baseline of new understanding, and with the guidance of a scientific advisory board (SAB), we will pursue regimen modifications, including novel combination therapies, that most effectively mitigate resistance emergence.

Publications

10 25 50
 
Description Conference Co-Chair HFP2024: Molecular mechanisms of host-pathogen interactions and virulence in human fungal pathogens
Geographic Reach Multiple continents/international 
Policy Influence Type Influenced training of practitioners or researchers
Impact The number of early career participants (students and post-doctoral fellows) was 120. In addition, we accepted 30 junior and senior investigators in order to promote discussions on scientific issues from many different angles.
URL https://www.febs.org/event/hfp2024-molecular-mechanisms-of-host-pathogen-interactions-and-virulence-...
 
Description Incident Management Team
Geographic Reach National 
Policy Influence Type Participation in a guidance/advisory committee
Impact Incident management team (run by Health Security agency) set up in response to increasing number of cases in UK and ongoing outbreaks at 2 large Trusts.
 
Description President of British Mycological Society
Geographic Reach Multiple continents/international 
Policy Influence Type Contribution to new or improved professional practice
Impact Delivered programme of monthly online talks, participated in the International Mycological Congress, launched the BMS and ISM's inaugural Naresh Magan Lecture Award and networking event for BMS members - was very well received, attracting around 60 people from across the globe. BMS members were awarded research grants to facilitate new research directions or ideas. Awarded UG student vacation bursary's to six students, supervised by BMS members in research centres across Scotland, England and Wales and covering diverse areas of mycological research. 11 small grants have been awarded through the year, supporting a range of activities including participation in meetings and practical courses, and purchase of equipment for projects. Six postgraduate members have been supported by the Eunice Jones bequest fund (purpose is to fund postgraduate students to visit laboratories to undertake collaborative work, or to attend conferences or workshops) Two music-themed projects supported by the Massee Arts Grant.
URL https://www.britmycolsoc.org.uk/events.html
 
Description UKRI Chair: Transdisciplinary AMR neworks
Geographic Reach National 
Policy Influence Type Participation in a guidance/advisory committee
Impact By convening transdisciplinary teams to tackle the problem of AMR, this funding scheme will support: Development of novel methods, technologies or common frameworks for data collection and analysis or modelling, including for example, rapid pathogen sequencing and antimicrobial usage, integration of diverse data sets yielding new opportunities for transdisciplinary research Work to improve data collection and standardisation Work on impact of climate change on AMR Development and evaluation of multifaceted evidence-based interventions, for example social, cultural and economic strategies that go beyond pharmaceutical and chemical interventions Study of AMR in crop production, including impacts on other reservoirs of resistance and on food security
URL https://www.ukri.org/opportunity/transdisciplinary-funding-to-tackle-antimicrobial-resistance-amr/
 
Description COMBAT-Candida
Amount £6,750,000 (GBP)
Organisation University of the Witwatersrand 
Sector Academic/University
Country South Africa
Start 01/2025 
End 12/2032
 
Description CandiNET-JPIAMR IMPACT
Amount £1,100,000 (GBP)
Organisation Radboud University Nijmegen 
Sector Academic/University
Country Netherlands
Start 01/2025 
End 04/2025
 
Description Development of Novel Antifungal Drugs
Amount £17,000,000 (GBP)
Funding ID WT5752757 
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 03/2025 
End 03/2030
 
Description Miltefosine - a dual purpose antifungal to mitigate antifungal resistance
Amount £473,000 (GBP)
Organisation Newcastle University 
Country United Kingdom
Start 09/2024 
End 09/2026
 
Description Basilea, Mycovia, LifeArc, Mylan-DnDi, Mundipharma, GSK, GILEAD, 
Organisation GlaxoSmithKline (GSK)
Country Global 
Sector Private 
PI Contribution Partnerships were established to assess fungal susceptibility to extant and near to market antifungals as combination therapies.
Collaborator Contribution The supply of antifungal drugs
Impact Data
Start Year 2024
 
Description CandiNET- JPIAMR IMPACT 
Organisation Radboud University Nijmegen
Country Netherlands 
Sector Academic/University 
PI Contribution Tihana Bicanic established the CandiNET- JPIAMR IMPACT team.
Collaborator Contribution A new collaboration established between St George's, Radboud, NL (Frank van der Veerdonk) and Pasteur (Alanio)/ Hopital St Louis in Paris (Denis), as well as Govender (Wits) to share clinical samples and data from 4 candidaemia clinical cohorts to identify host and pathogen treatment response biomarkers in candidaemia
Impact JPIAMR grant to T Bicanic for CandiNet project €1.1 mil (UKRI portion £346K)
Start Year 2024
 
Description Tripartite catalyst for antifungal drug discovery 
Organisation University of Dundee
Department Drug Discovery Unit
Country United Kingdom 
Sector Academic/University 
PI Contribution We developed methods for high throughput screening of antifungal drug susceptibility & time-killing that will be utilised for novel drug discovery, with a particular emphasis on drugs that are effective against Candida auris and Cryptococcus neoformans.
Collaborator Contribution DDU have developed workflows (includung libraries of small molecules) for drug discovery that will be pivoted towards the identification of novel mode of action antifungal drugs.
Impact A multidisciplinary consortium has been assembled, including industry partners GSK. A 5 year Wellcome Trust grant, total value more than £17m has been awarded, with £2.2m to MRC CMM.
Start Year 2024
 
Description Conference presentation INFOCUS Colombia: Mitigating fAMR via combination therapy 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact The INFOCUS LATAM ISHAM associated Working Group was created in 2019 taking advantage of the extensive network of players in the field of Medical Mycology that have been working under the umbrella of the INFOCUS meeting since 2002.

The main proposals of the INFOCU-LATAM are: (i) to connect graduate students and health care workers interested in contributing to the development of local educational programs and guidelines for improving the early diagnosis and best clinical management of patients with fungal infections in our region; (ii) to promote and facilitate the conduction of collaborative multicenter studies delineated to understand the epidemiology of fungal infections in LATAM, (iii) to encourage advocacy initiatives necessary to convince health policy makers and hospital managers to provide better support to medical assistance to patients suffering from opportunistic and endemic fungal infections in our region.
Year(s) Of Engagement Activity 2024
URL https://www.infocuslatam.org/news-infocus-latam/infocus-2024-22-infocus-latinoamerica/37/2
 
Description Finding Genius Podcast with Richard Jacobs 2024. Killer Fungi: Exploring The Silent Threat To Global Health With Professor Neil Gow 
Form Of Engagement Activity A broadcast e.g. TV/radio/film/podcast (other than news/press)
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Media (as a channel to the public)
Results and Impact Explores NG's role in revolutionizing the future of antifungal drugs, fungi resistance, and immunotherapies for fungal diseases? How do fungi escape early detection?

Common versus serious human interactions with fungi.
When we are most vulnerable to fungal infections.
How many people a year die from fungal infections, and why this number has risen.
The "big four" deadly fungi.
Why there so few doctors trained to recognize fungal infections.
Year(s) Of Engagement Activity 2024
URL http://tinyurl.com/bddjkeve
 
Description Presentation at All Things Fungi Festival 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Public/other audiences
Results and Impact ATF is an educational and community-oriented festival involving local and national fungi groups. Using Fungi as the focus the festival aims to cover Mushroom identification, cultivation, microscopy, DNA sequencing and topics surrounding the soil food web, composting, permaculture & and rewilding. Most importantly, it celebrates the people at the forefront of mycology in the UK and beyond.
My presentation "From Bugs to Drugs" addressed the enormous threat posed by fungal pathogens, and antifungal drug resistance and new strategies for tackling this.
Year(s) Of Engagement Activity 2024
URL https://www.allthingsfungi.co.uk/about-1
 
Description World Fungus Day Online Presentation 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Public/other audiences
Results and Impact Through UK Fungus Day, the British Mycological Society shares the importance of fungi to our lives and aims to inspire others to help preserve our native fungi and improve our scientific knowledge of these unique and remarkable organisms. Fungi Around the World brought together 12 mycologists from around the globe to deliver online symposia in all time zones via 3 workshops.
My presentation "From Bugs to Drugs" addressed the enormous threat posed by fungal pathogens, and antifungal drug resistance and new strategies for tackling this.
Year(s) Of Engagement Activity 2008,2024
URL https://www.ukfungusday.co.uk/webinar